CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 10-Q — Nov 13, 2026
CERo Therapeutics Holdings reported a going-concern warning in its Q3 2026 10-Q, holding just $650,681 in cash against a working capital deficit of approximately $19.3 million and a stockholders' deficit of $18.8 million. Management stated that available cash will not fund operations for one year, and the company used $8.1 million of cash in operations over the first nine months of 2026. The quarter's reported net income of $4.0 million was driven entirely by non-cash items, including a $3.8 million gain on debt extinguishment and a $3.7 million gain from revaluing preferred stock liabilities, not by operations.
Key figures
- Total Debt
- 8126403
- Cash Position
- 650681
- Shares Outstanding
- 83309742
- Q3 basic eps
- 0.06
- Q3 net income
- 4019112
- Reverse splits
- 1-for-100 (Jan 2025) and 1-for-20 (Jun 2025)
- Keystone commitment
- 25000000
- Working capital deficit
- approximately $19.3 million
- Convertible notes proceeds
- 4485200
- Consolidated note principal
- 5666109
- Gain on debt extinguishment
- 3801413
- Gain on preferred stock liabilities 9m
- 10335126
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.